Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Christian Dejaco, Bastian Oppl, Paul Monach, David Cuthbertson, Simon Carette, Gary Hoffman, Nader Khalidi, Curry Koening, Carol Langford, Kathleen McKinnon-Maksimowicz, Philip Seo, Ulrich Specks, Steven R Ytterberg, Peter A. Merkel, Jochen Zwerina

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80%of patients were using glucocorticoids and 68%additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.

Original languageEnglish (US)
Article numbere0121737
JournalPLoS One
Volume10
Issue number3
DOIs
StatePublished - Mar 26 2015

Fingerprint

Granulomatosis with Polyangiitis
Biomarkers
biomarkers
Immunoglobulin G
glucocorticoids
Serum
immunosuppressive agents
Glucocorticoids
Immunosuppressive Agents
prednisone
relapse
remission
eosinophils
Prednisone
Eosinophils
drugs
chemokine CCL26
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Dejaco, C., Oppl, B., Monach, P., Cuthbertson, D., Carette, S., Hoffman, G., ... Zwerina, J. (2015). Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One, 10(3), [e0121737]. https://doi.org/10.1371/journal.pone.0121737

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). / Dejaco, Christian; Oppl, Bastian; Monach, Paul; Cuthbertson, David; Carette, Simon; Hoffman, Gary; Khalidi, Nader; Koening, Curry; Langford, Carol; McKinnon-Maksimowicz, Kathleen; Seo, Philip; Specks, Ulrich; Ytterberg, Steven R; Merkel, Peter A.; Zwerina, Jochen.

In: PLoS One, Vol. 10, No. 3, e0121737, 26.03.2015.

Research output: Contribution to journalArticle

Dejaco, C, Oppl, B, Monach, P, Cuthbertson, D, Carette, S, Hoffman, G, Khalidi, N, Koening, C, Langford, C, McKinnon-Maksimowicz, K, Seo, P, Specks, U, Ytterberg, SR, Merkel, PA & Zwerina, J 2015, 'Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)', PLoS One, vol. 10, no. 3, e0121737. https://doi.org/10.1371/journal.pone.0121737
Dejaco, Christian ; Oppl, Bastian ; Monach, Paul ; Cuthbertson, David ; Carette, Simon ; Hoffman, Gary ; Khalidi, Nader ; Koening, Curry ; Langford, Carol ; McKinnon-Maksimowicz, Kathleen ; Seo, Philip ; Specks, Ulrich ; Ytterberg, Steven R ; Merkel, Peter A. ; Zwerina, Jochen. / Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). In: PLoS One. 2015 ; Vol. 10, No. 3.
@article{0497b55aafb341a09a1f7afcf5b126a8,
title = "Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
abstract = "Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80{\%}of patients were using glucocorticoids and 68{\%}additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.",
author = "Christian Dejaco and Bastian Oppl and Paul Monach and David Cuthbertson and Simon Carette and Gary Hoffman and Nader Khalidi and Curry Koening and Carol Langford and Kathleen McKinnon-Maksimowicz and Philip Seo and Ulrich Specks and Ytterberg, {Steven R} and Merkel, {Peter A.} and Jochen Zwerina",
year = "2015",
month = "3",
day = "26",
doi = "10.1371/journal.pone.0121737",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

AU - Dejaco, Christian

AU - Oppl, Bastian

AU - Monach, Paul

AU - Cuthbertson, David

AU - Carette, Simon

AU - Hoffman, Gary

AU - Khalidi, Nader

AU - Koening, Curry

AU - Langford, Carol

AU - McKinnon-Maksimowicz, Kathleen

AU - Seo, Philip

AU - Specks, Ulrich

AU - Ytterberg, Steven R

AU - Merkel, Peter A.

AU - Zwerina, Jochen

PY - 2015/3/26

Y1 - 2015/3/26

N2 - Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80%of patients were using glucocorticoids and 68%additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.

AB - Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80%of patients were using glucocorticoids and 68%additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.

UR - http://www.scopus.com/inward/record.url?scp=84926315973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926315973&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0121737

DO - 10.1371/journal.pone.0121737

M3 - Article

C2 - 25812008

AN - SCOPUS:84926315973

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0121737

ER -